openPR Logo
Press release

Deadline on Oct. 28th coming up in Lawsuit for Investors who lost money with shares of Sage Therapeutics, Inc. (NASDAQ: SAGE)

A Deadline is coming up on October 28, 2024 in the lawsuit for certain investors in Sage Therapeutics, Inc. (NASDAQ: SAGE).

A Deadline is coming up on October 28, 2024 in the lawsuit for certain investors in Sage Therapeutics, Inc. (NASDAQ: SAGE).

A deadline is coming up on October 28, 2024 in the lawsuit filed for certain investors of Sage Therapeutics, Inc. (NASDAQ: SAGE) over alleged securities laws violations by Sage Therapeutics, Inc.

Investors who purchased shares of Sage Therapeutics, Inc. (NASDAQ: SAGE) have certain options and there are strict and short deadlines running. Deadline: October 28, 2024. NASDAQ: SAGE stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Sage Therapeutics, Inc. (NASDAQ: SAGE) common shares between April 12, 2021 and July 23, 2024, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 12, 2021 and July 23, 2024, the defendants made false and/or misleading statements and/or failed to disclose that zuranolone was less effective in treating MDD than Defendants had led investors to believe, that accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone's clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated, that SAGE-718 was less effective in treating MCI due to PD than Defendants had led investors to believe, that accordingly, SAGE-718's clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated, that SAGE-324 was less effective in treating ET than Defendants had led investors to believe, thataccordingly, SAGE-324's clinical, regulatory, and commercial prospects as a treatment for ET were overstated, and that as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Sage Therapeutics, Inc. (NASDAQ: SAGE) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on Oct. 28th coming up in Lawsuit for Investors who lost money with shares of Sage Therapeutics, Inc. (NASDAQ: SAGE) here

News-ID: 3713067 • Views:

More Releases from Shareholders Foundation, Inc.

Investigation announced for Investors in shares of XPLR Infrastructure, LP (NYSE: XIFR) over possible Wrongdoing
Investigation announced for Investors in shares of XPLR Infrastructure, LP (NYSE …
An investigation was announced for long-term investors in shares of XPLR Infrastructure, LP (NYSE: XIFR) concerning potential breaches of fiduciary duties by certain directors of XPLR Infrastructure, LP. Investors who are current long term investors in XPLR Infrastructure, LP (NYSE: XIFR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Civitas Resources, Inc. (NYSE: CIVI)
Lawsuit filed for Investors who lost money with shares of Civitas Resources, Inc …
An investor, who purchased shares of Civitas Resources, Inc. (NYSE: CIVI), filed a lawsuit alleged violations of Federal Securities Laws by Civitas Resources, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Civitas Resources, Inc. (NYSE: CIVI) have certain options and for certain investors are short and strict deadlines running. Deadline: July 1, 2025. NYSE: CIVI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Investigation announced for Long-Term Investors in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of Maravai LifeScience …
An investigation was announced for current long-term investors in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) concerning potential breaches of fiduciary duties by certain directors of Maravai LifeSciences Holdings, Inc. Investors who are current long term investors in Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current
Zynex, Inc. (NASDAQ: ZYXI) Investor Alert: Deadline in Lawsuit on May 19, 2025
Zynex, Inc. (NASDAQ: ZYXI) Investor Alert: Deadline in Lawsuit on May 19, 2025
A deadline is coming up on May 19, 2025 in the lawsuit filed for certain investors of Zynex, Inc. (NASDAQ: ZYXI) over alleged securities laws violations by Zynex, Inc. Investors who purchased shares of Zynex, Inc. (NASDAQ: ZYXI) have certain options and there are strict and short deadlines running. Deadline: May 19, 2025. Zynex, Inc. (NASDAQ: ZYXI) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for SAGE

A Sage and Wise Choice Between Sage 50 (Simply Accounting) And Quickbooks
Brandon, MB––November 27, 2021: Sage 50 previously known as Peachtree or Simply Accounting traces its roots back to 1976 as part of The Computer SystemCenter – a microcomputer dealer. Peachtree was included in the initial launch of the first IBM PCs in 1981. By 1984, Peachtree was the seventh largest microcomputer software company generating nearly $22 million in revenue. Sage Group acquired Peachtree in the late 1990s and changed the product
Investigation announced for Investors in shares of Sage Therapeutics, Inc. (NASD …
An investigation on behalf of investors of Sage Therapeutics, Inc. (NASDAQ: SAGE) shares over potential securities laws violations by Sage Therapeutics, Inc. and certain of its directors and officers in connection with certain financial statements was announced. Investors who purchased shares of Sage Therapeutics, Inc. (NASDAQ: SAGE), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on
The future of Sage SalesLogix unveiled at DMC Software with Sage workshops
Sage Saleslogix Business Partner of the Year, DMC Software Solutions, are hosting Sage SalesLogix Workshops which identify how SalesLogix CRM can support organisational growth and provide previews of the forthcoming SalesLogix developments. The DMC Software SalesLogix Sage Events are scheduled for 28th and 29th June 2011 in Peterborough and London, respectively. CRM experts from Sage and DMC Software explore the business potential Saleslogix can help to achieve, with a look to
Sage VARs See Continued Marketing Successes with Sage Product Newsletters
Sage ERP, CRM, HR, and Nonprofit product newsletters continue to be one of the best ways to stay in front of customers and keep them engaged with targeted content. Laguna Hills, CA, March 09, 2011 -- Juice Marketing has revealed that their Sage ERP, CRM, HR, and nonprofit product newsletters continue to be a popular marketing tool among Sage VARs despite the growing popularity of social media like Twitter, Facebook, and
Sage India Offers Better Insight into Your Business with Sage Accpac Insight 5.4
New Delhi –2009, Sage Software announced today the availability of Sage Accpac Insight 5.4, a new version of the company’s analysis and business intelligence tool for small and mid-sized businesses. Designed for use and integrated with Sage Accpac ERP1 (enterprise resource planning), Sage Accpac Insight utilizes key business data contained within Sage Accpac ERP, and is ideal for employees in remote offices and disparate departments who need to manage, distribute,
Agarwal Fasteners Tightens Operations with Sage Accpac ERP by Sage India
Agarwal Fasteners Tightens Operations with Sage Accpac ERP by Sage India • Real time view of inventory for informed procurement • Seamless integration of modules for zero duplication and errors • Automatic reports generated at the touch of a button • High data security for greater control New Delhi : Sage India, today announced that Agarwal Fasteners Pvt. Ltd., the specialized manufacturer of critical stainless steel fasteners as per industry standards